English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

45 Background: To describe the kinetics of hepatitis B core-related antigen (qHBcrAg) and anti-hepatitis 46 B core antibody (qAnti-HBc) during tenofovir (TDF)-treatment and assess their ability to predict 47 HBeAg-seroclearance in patients co-infected with HIV and hepatitis B virus (HBV). 48 Methods: Serum qHBcrAg, qAnti-HBc and HBV-DNA were obtained at TDF-initiation and every 6-12 49 months. On-treatment kinetics of qHBcrAg (ΔqHBcrAg) and qAnti-HBc (ΔqAnti-HBc) were estimated 50 using mixed-effect linear regression. Hazard ratios (HR) assessing the association between markers 51 and HBeAg-seroclearance were calculated using proportional hazards regression and sensitivity (Se) 52 and specificity (Sp) of marker levels in predicting HBeAg-seroclearance were assessed using time53 dependent ROC curves. 54 Results: During a median 4.6 years, cumulative incidence of HBsAg-seroclearance and HBeAg55 seroclearance were 3.2% (n=5/158) and 27.4% (n=26/95), respectively. ΔqHBcrAg was biphasic in 56 HBeAg-positive (-0.051 and -0.011 log10U/mL/month during <18 months and >18 months, 57 respectively) and monophasic in HBeAg-negative patients. ΔqAnti-HBc was monophasic regardless of 58 HBeAg-status. In HBeAg-positive patients, baseline qHBcrAg and qAnti-HBc levels were associated 59 with HBeAg-seroclearance (adjusted-HR=0.48/log10U/mL; 95%CI=0.33-0.70 and unadjusted60 HR=1.49/log10PEIU/mL; 95%CI=1.08-2.07, respectively). Cutoffs with the highest accuracy in 61 predicting HBeAg-seroclearance at 36 months were qHBcrAg<6.5 log10U/mL at month-24 62 (Se=1/Sp=0.58) and baseline qAnti-HBc>4.1 log10PEIU/mL (Se=0.42/Sp=0.81). 63 Conclusions: In co-infected patients undergoing TDF, qHBcrAg/qAnti-HBc could be of use in 64 monitoring HBeAg-seroclearance. 65 66

the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases

Erratum to: Kinetics of Hepatitis B Core–Related Antigen and Anti–Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus–Hepatitis B Coinfection